Telomir raises $5.6M in common-stock PIPE at $1.16/share; DeJoria adds $1.0M

Telomir Pharmaceuticals, Inc.

PIPE of 4,843,300 common shares at $1.16/share, a 5% discount to the 10-day VWAP ending two days before the Oct. 5, 2026 closing; gross proceeds ~$5.6M.
Existing significant shareholder John Paul DeJoria (reported ~3.55M shares, ~5.0% of outstanding) invested an additional $1.0M; other existing and new investors also participated.
Alexander Capital placed the deal: 9.0% cash fee (~$455,000), expense reimbursement capped at $40,000, plus 387,464 five-year warrants at $1.16/share.
Net proceeds fund Telomir-Zn's Phase 1/2 trial in advanced or metastatic triple-negative breast cancer under an FDA-cleared IND, plus working capital and general corporate purposes.
No investor warrants, convertibles or price-reset features; Telomir must file a resale registration statement within 30 days of closing.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.